735 results on '"Kwon, Eugene D."'
Search Results
2. Survival Patterns Based on First-site–specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?
3. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going
4. MP60-16 PSMA-PET GUIDED METASTASIS DIRECTED THERAPY FOR OLIGOMETASTATIC PROSTATE CANCER
5. MP60-07 PREDICTORS OF RESPONSE TO METASTASIS DIRECTED THERAPY (MDT) IN PROSTATE CANCER PATIENTS WITH SOLITARY METASTASES TREATED WITH MDT
6. MP60-14 SURVIVAL PATTERNS BASED ON SITE-SPECIFIC VISCERAL METASTASIS IN METASTATIC PROSTATE CANCER PATIENTS: ARE OUTCOMES OF VISCERAL METASTASES THE SAME?
7. MP52-01 PSMA-PET FOR INITIAL BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY
8. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies
9. Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity
10. Neurologic Symptoms After 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience.
11. Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients
12. Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS
13. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer
14. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies.
15. Prostate Cancer and Malignant Ascites: The Mayo Clinic Experience With a Rare and Aggressive Disease Progression.
16. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer
17. Prostate Cancer and Malignant Ascites: The Mayo Clinic Experience with a Rare and Aggressive Disease Progression
18. Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis
19. Low PSA radiographic disease progression on C11‐choline PET
20. The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
21. Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT
22. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
23. Low PSA radiographic disease progression on C11‐choline PET.
24. Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis.
25. Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.
26. Genomic predictors of response and resistance to 177-Lu-PSMA-617 using circulating tumor DNA.
27. Outcomes for patients with mCRPC and liver metastasis receiving 177-Lu-PSMA-617 treatment.
28. Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic Magnetic Resonance Imaging
29. Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease
30. Costimulatory B7-H1 in Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
31. Supplemental Figure Legend from PD-1 Restrains Radiotherapy-Induced Abscopal Effect
32. Supplemental Figure 1 from PD-1 Restrains Radiotherapy-Induced Abscopal Effect
33. Data from PD-1 Restrains Radiotherapy-Induced Abscopal Effect
34. MP11-10 ISOLATED IN-FIELD RECURRENCE FOLLOWING RADICAL PROSTATECTOMY AND RADIATION
35. Retrospective Review of Percutaneous Image-Guided Ablation of Oligometastatic Prostate Cancer: A Single-Institution Experience
36. Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography
37. T Cell Infiltration of the Prostate Induced by Androgen Withdrawal in Patients with Prostate Cancer
38. Elimination of Residual Metastatic Prostate Cancer after Surgery and Adjunctive Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) Blockade Immunotherapy
39. Manipulation of T Cell Costimulatory and Inhibitory Signals for Immunotherapy of Prostate Cancer
40. Supplementary Figures S1-S3 from T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival
41. Supplementary Table 1 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
42. Data from Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
43. Supplementary Figure 1 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
44. Legend for Supplemental Figure 2legend from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma
45. Supplementary Figure 3 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
46. Supplementary Table 2 from Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT–Identified Oligometastatic Castration-Resistant Prostate Cancer
47. Supplementary Data from Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
48. Supplementary Figures 1-6 from B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for Therapy
49. Characterizing changes in tumor mutational burden (TMB) by serial circulating tumor DNA (ctDNA) testing in patients with advanced prostate cancer (aPC).
50. Prognostic value of C-11 choline PET/CT scan in patients with metastatic castration resistant prostate cancer (m-CRPC) undergoing treatment with radium-223.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.